Fibroblast activation protein (FAP) is a transmembrane serine peptidase that belongs to the prolyl peptidase family. FAP has been implicated in cancer; however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed. To identify peptide motifs for FAP-selective inhibitor design, we used P 2 -Pro 1 and acetyl (Ac)-P 2 -Pro 1 dipeptide substrate libraries, where P 2 was varied and substrate hydrolysis occurs between Pro 1 and a fluorescent leaving group. With the P 2 -Pro 1 library, FAP preferred Ile, Pro, or Arg at the P 2 residue; however, DPP-4 showed broad reactivity against this library, precluding selectivity. By contrast, with the Ac-P 2 -Pro 1 library, FAP cleaved only Ac-Gly-Pro, whereas DPP-4 showed little reactivity with all substrates. FAP also cleaved formyl-, benzyloxycarbonyl-, biotinyl-, and peptidyl-GlyPro substrates, which DPP-4 cleaved poorly, suggesting an N-acylGly-Pro motif for inhibitor design. Therefore, we synthesized and tested the compound Ac-Gly-prolineboronic acid, which inhibited FAP with a K i of 23 ؎ 3 nM. This was ϳ9-to ϳ5400-fold lower than the K i values for other prolyl peptidases, including DPP-4, DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase. These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl-Gly-Pro-based inhibitors will allow testing of FAP as a therapeutic target.
Tumor-associated stromal cells can promote epithelial tumorigenesis (1, 2) , suggesting that stromal proteins may represent novel therapeutic targets. Fibroblast activation protein (FAP), 2 a transmembrane serine peptidase, is one potential target because it is highly expressed by stromal fibroblasts in most epithelial cancers (3) (4) (5) (6) (7) . Increased FAP expression in tumors correlates with increased FAP activity relative to normal tissues (8, 9) , and FAP overexpression promotes tumorigenesis in xenograft models (10 -12) . This effect requires catalytically active FAP (12) , suggesting that FAP activity promotes tumor growth and that FAP inhibition may have therapeutic value.
FAP belongs to the prolyl peptidase family, which comprises serine proteases that typically cleave peptide substrates after a proline residue. This family has been implicated in several diseases, including diabetes, cancer, and mood disorders (13, 14) , and includes dipeptidyl peptidase-4 (DPP-4), DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, acylpeptide hydrolase, and prolyl carboxypeptidase. These proteases differ in structure at the N terminus, but each has a C-terminal ␣␤-hydrolase domain that contains the catalytic Ser, Asp, and His residues. FAP, like its most closely related family member, DPP-4, is a type II transmembrane protein; both have a short cytoplasmic tail, a transmembrane domain, and a ␤-propeller domain containing several sites of N-linked glycosylation (5, (15) (16) (17) (18) (19) (20) . Crystallographic data for FAP and DPP-4 show that the ␤-propeller has important substrate binding sites and suggest that this domain precludes access of large substrates to the ␣␤-hydrolase domain (15) (16) (17) (18) (19) (20) (21) .
DPP-4 regulates biological processes by cleaving regulatory peptides of Ͻ ϳ10 kDa, including glucagon-like peptide-1, glucose-dependent insulinotropic peptide, and stromal-derived factor-1 (22) (23) (24) (25) . DPP-4 cleaves these peptides via a well characterized dipeptidyl peptidase activity that removes P 2 -Pro 1 or P 2 -Ala 1 dipeptides, (P 2 represents any amino acid) from the N terminus of the substrate. DPP-4 similarly cleaves P 2 -Pro 1 -based synthetic peptides and does so with high catalytic efficiency and broad specificity (25, 26) . In contrast, endogenous peptide substrates of FAP are not known, and the activity of the protease against synthetic substrates remains poorly characterized. FAP also cleaves proteins such as gelatin (8, 27) and ␣ 2 -antiplasmin (28), suggesting that the two proteases cleave distinct substrates.
The dipeptidase inhibitor Val-BoroPro shows efficacy in tumor models (12, 29) that correlates with FAP inhibition (12) . However, because Val-BoroPro also inhibits DPP-4, -7, -8, and -9 (30 -32), its mechanism of action remains unclear. To overcome this lack of selectivity, we sought here to define the substrate specificity of FAP with the goal of identifying a FAP-selective motif for inhibitor design. We identified N-acyl-Gly-Pro dipeptides as FAP-selective substrate motifs and synthesized a representative boronic acid inhibitor, Ac-Gly-BoroPro. This inhibitor showed ϳ9-to ϳ5400-fold selectivity for FAP inhibition relative to other prolyl peptidases, suggesting that N-acyl-Gly-Pro-based inhibitors will aid in testing whether FAP is a valid therapeutic target.
phore. Acetylated substrates were prepared by treating peptides on resin with acetic anhydride in 10% triethylamine/dichloromethane until the resin was negative to the Kaiser ninhydrin test (34) . Formylated substrates were prepared as described (35) . Ac-Gly-Proline boronic acid (BoroPro) was synthesized as described by Gibson et al. (36) except that Ac-Gly was substituted for Val, making deprotection unnecessary. Substrates and inhibitors were purified by reverse phase chromatography and verified by matrix-assisted laser-desorption ionization mass spectrometry. N-glycanase was from Sigma.
Protease Cloning and Expression-cDNAs encoding the extracellular domains of FAP (amino acids 38 -760) and DPP-4 (amino acids 39 -766) were generated by polymerase chain reaction (PCR) using Quick Clone cDNA library (Stratagene) as a template. PCR products were TA-cloned into pGemT (Promega) and confirmed by DNA sequencing. Confirmed cDNAs were then subcloned into pFLAG-CMV1 (Sigma) for expression as N-terminal FLAG-tagged proteins. Plasmids containing full-length DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase were obtained from Origene and used as templates to generate pFLAG-CMV1 expression constructs encoding each protease as above. These constructs encoded amino acids 26 -492 of DPP-7, 2-883 of DPP-8, 2-864 of DPP-9, 2-710 of prolyl oligopeptidase, and 2-732 of acylpeptide hydrolase.
For protein production, we transfected 293 cells with plasmids encoding proteases using calcium phosphate and purified proteins from serum-free conditioned medium by affinity chromatography with M2-anti-FLAG resin (Sigma). Proteins were Ͼ95% pure as determined by SDS-PAGE with Coomassie Blue staining, with the exception of DPP8, which had a purity of ϳ70%. Protein concentrations were determined by the bichinconic acid method (Bio-Rad).
Gel Filtration Chromatography and Light Scattering Analysis-To calculate the stoichiometry of purified FAP and DPP-4, we measured the molecular mass of each protease in solution using multiangle light scattering in combination with gel filtration chromatography and interferometric refractometry. This method allows accurate determination of the molecular mass of a protein based on protein concentration, refractive index, and the degree of light scattering (37) . Proteases (50 g) in 50 mM Tris (pH 7.4), and 100 mM NaCl were loaded onto a Shodex KW-803 gel filtration column (flow rate 0.5 ml/min). The column was developed using an Agilent 1100 HPLC system with a MiniDawn 3-angle light scattering detector (Wyatt Technology) and an OPTILAB DSP interferometric refractometer (Wyatt Technology) in line. ASTRA software was used for molecular mass calculations.
Protease Assays-Protease activity was monitored continuously using a SpectraMax M2 microplate reader (Molecular Devices) in the kinetic mode. Assays were conducted at 23°C in 50 mM Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA. The excitation/emission wavelengths were 360/460 nm for AMC/AMCC substrates and 400/505 nm for AFC substrates. Standard curves of the appropriate fluorescent product versus concentration were used to convert relative fluorescence units to moles of product produced. Generally, kinetic constants (k cat , K m ) were determined with initial rate (v 0 ) measurements, using substrate concentrations in the range of 0. Inhibition Kinetics-K i values for inhibition of proteases by Ac-GlyBoroPro were determined using the method of progress curves for analysis of tight binding competitive inhibitors (39, 40) . Briefly, proteases were added to a reaction mixture containing inhibitor and substrate (Ac-Ala-AMC for acylpeptide hydrolase, Z-Gly-Pro-AMC for prolyl oligopeptidase, and Ala-Pro-AFC for all others) in assay buffer at 23°C. Protease activity was followed continuously as described above to monitor time-dependent inhibition. Reactions contained inhibitor concentrations at least 20-fold greater than protease concentrations, such that the protease-inhibitor complex does not significantly deplete the free inhibitor. Data were plotted as v 0 /v i Ϫ 1 versus [I], where v 0 is the rate of substrate hydrolysis in the absence of inhibitor, v i is the steady state rate of substrate hydrolysis in the presence of inhibitor, and [I] is the concentration of Ac-Gly-BoroPro. Plots of v 0 /v i Ϫ 1 versus [I] were linear, and the apparent inhibition constant, K app , was determined from the reciprocal of the slope. K i , the true equilibrium inhibition constant, was determined according to the following relationship:
is the concentration of substrate used in the assay and K m is the Michaelis constant for substrate cleavage.
RESULTS

Protease Expression and Characterization-DPP-4 exists in serum as
a soluble glycoprotein beginning at residue 39 (41) . We therefore expressed and purified recombinant Ser-39-DPP-4 and an analogous soluble FAP molecule beginning at amino acid Thr-38. When analyzed by SDS-PAGE under reducing conditions, FAP migrated with an apparent molecular mass of 97 kDa (Fig. 1A) , whereas DPP-4 migrated with a molecular mass of 105-115 kDa (Fig. 1B) . These molecular masses are 15-20 kDa greater than expected based on primary amino acid sequence and decreased upon treatment with N-glycanase (not shown), indicating that each protease is N-glycosylated. To further characterize each protease, we determined molecular mass in solution using multiangle light scattering in combination with gel filtration chromatography and interferometric refractometry. This analysis showed that FAP exists predominantly as a dimer with a molecular mass of 200 Ϯ 15 kDa (Fig. 1A) . Small amounts of monomeric (elution volume 9.0 ml) and multimeric (elution volume Ͻ8.0 ml) FAP were also observed. The predominant elution peak of DPP-4 had a molecular mass of 220 Ϯ 15 kDa (Fig. 1B) , indicating a dimeric composition. The dimeric nature of our soluble protease preparations is consistent with the dimeric composition of FAP and DPP-4 crystal structures (15) (16) (17) (18) (19) , suggesting that they are structurally intact.
Dipeptide Substrate Specificity-Although FAP cleaves certain proline-containing DPP-4 substrates (8, 15) , the full spectrum of dipeptidase specificity of FAP remains undefined. Therefore, to better understand the specificity of FAP, we examined the activity of the protease against a P 2 -Pro 1 -AMCC dipeptide substrate library (Fig. 2) , where P 2 was varied with all amino acids (except Cys and Trp) and amide bond hydrolysis occurs between the P 1 Pro and the fluorogenic leaving group, AMCC. Even though DPP-4 can cleave dipeptides with a P 1 Ala residue, we limited the P 1 position of our library to Pro because FAP showed little activity against P 2 -Ala dipeptide substrates in preliminary studies. The dipeptide cleavage profile of the library provides information regarding protease S 2 subsite specificity. As shown in Fig. 2A , FAP preferred Ile, Pro, and Arg in the P 2 position and showed little activity against dipeptides with Asp, His, or Asn in the P 2 position. DPP-4 readily cleaved all substrates in the library, indicating broad specificity at the S 2 subsite (Fig. 2B) .
Kinetic Constants for Cleavage of Dipeptide Substrates-To extend the results obtained with the dipeptide substrate library, we determined kinetic parameters for cleavage of commercially available dipeptide substrates by FAP ( Table 1 ). The catalytic efficiency (k cat /K m ) for substrate cleavage was greatest with Ile-Pro-AFC, followed by Ala-Pro-, Gly-Pro-, and Phe-Pro-AFC, consistent with the dipeptide substrate library results (Fig. 2) . With the exception of Ile-Pro-AFC, these differences reflect differences in k cat values, as the K m for each substrate was ϳ250 M. The greater catalytic efficiency observed for Ile-Pro-AFC hydrolysis was due to both k cat and K m effects as the observed K m was ϳ2.5-fold lower than the other P 2 -Pro 1 -AFC substrates. FAP showed markedly less activity against P 2 -Ala 1 -based substrates. GA-AMC was not cleaved, and the catalytic efficiency for Lys-Ala-AFC cleavage was 400 -1000-fold less than the catalytic efficiency for cleavage of P 2 -Pro 1 -based peptides ( Table 1 ), indicating that FAP prefers Pro in the P 1 position. were expressed and purified as described under "Experimental Procedures." Each protein was then subjected to SDS-PAGE under reducing conditions (left panels) and analyzed by gel filtration chromatography and multiangle light scattering (right panels). The molecular mass value determined across the predominant peak in each chromatogram is indicated (average Ϯ S.D.; n ϭ 3). FIGURE 2. FAP and DPP-4 have distinct dipeptide substrate specificities. FAP (37 nM) and DPP-4 (6.8 nM) were reacted with P 2 -Pro 1 -AMCC (1 M; top panels) and acetyl-P 2 -Pro 1 -AFC (10 M; bottom panels) dipeptide substrates, where P 2 was varied with all amino acids (except Cys and Trp). Initial rates of substrate hydrolysis were determined as described under "Experimental Procedures." Amino acid residues are shown in singleletter code.
For comparison, we determined kinetic constants for cleavage of AlaPro-AFC and Gly-Pro-AFC by DPP-4 ( Table 1 ). The catalytic efficiency for Ala-Pro-AFC hydrolysis was greater than that for Gly-Pro-AFC, consistent with the dipeptide library. Strikingly, the catalytic efficiencies for dipeptide hydrolysis by DPP-4 were consistently ϳ100-fold greater than observed with FAP, reflecting both an increase in k cat and decrease in K m .
N-acetyl-dipeptide Substrate Specificity-Given reports suggesting that FAP has endopeptidase activity (8, 28), we next examined the endopeptidase specificity of the protease. For this, we assayed FAP against an Ac-P 2 -Pro 1 -AFC substrate library in which the acetyl group forms an amide bond with the P 2 amino acid, thereby mimicking an endopeptidase substrate. Thus, in contrast with the P 2 -Pro 1 library, which contains a free N terminus, the acetylated library is N-terminal blocked. FAP showed a marked preference for a P 2 Gly residue in the acetylated library, having little activity against all other substrates in the library (Fig. 2C) . Strikingly, DPP-4 had little activity against Ac-Gly-Pro-AFC and all other substrates in the acetylated library (Fig. 2D) . These data suggest that DPP-4 has limited endopeptidase activity and that FAP endopeptidase activity is restricted to Gly-Pro-containing substrates.
Kinetic Analysis of Gly-Pro-and Ac-Gly-Pro-AFC Hydrolysis-In light of the Ac-P 2 -Pro 1 -AFC library results, we performed kinetic analyses with Ac-Gly-Pro-AFC and Gly-Pro-AFC substrates as their hydrolysis rates may be directly compared. FAP cleaved each substrate with similar efficiency as shown in Fig. 3A . FAP showed a moderate increase in K m (330 Ϯ 30 M) for Ac-Gly-Pro-AFC relative to Gly-Pro-AFC (Table 1) ; however, a concomitant increase in k cat (7.7 Ϯ 0.2 s Ϫ1 ) for the acetylated substrate resulted in an equivalent catalytic efficiency for both substrates. By contrast, DPP-4 only showed significant activity against Gly-Pro-AFC (Fig. 3B) . The catalytic efficiency for cleavage of Ac-Gly-Pro-AFC by DPP-4 was equivalent to 36 Ϯ 3 M Ϫ1 s Ϫ1 when determined under pseudo-first order conditions. This value is over four orders of magnitude lower than that for cleavage of Gly-Pro-AFC (Table  1) , indicating a marked preference for the substrate with a free N terminus.
Cleavage of N-substituted-Gly-Pro-AMCC Substrates-To test whether FAP could cleave other N-substituted-Gly-Pro-based substrates, we synthesized N-blocked dipeptide substrates (N-methyl-, formyl-, succinyl-, benzyloxycarbonyl-(Z-), biotinyl-Gly-Pro-AMCC) and a peptide modeled after the FAP cleavage site in ␣ 2 -antiplasmin (Ac-Thr-Ser-Gly-Pro-AMCC) (28) . With the exception of succinylGly-Pro-AMCC, FAP cleaved all N-substituted-Gly-Pro-AMCC substrates at 35-165% of the rate for Gly-Pro-AMCC hydrolysis (Fig. 4B) , indicating that the protease tolerates other N-terminal blocking groups and a tetrapeptide substrate. Kinetic analysis with commercially available Z-Gly-Pro-AMC showed a catalytic efficiency of 7.4 Ϯ 0.6 ϫ 10 3 M Ϫ1 s Ϫ1 , which is ϳ3-fold lower than that for Gly-Pro-AFC (Table 1) , consistent with these results. In contrast with FAP, DPP-4 cleaved only N-methyl-Gly-Pro-AMCC at a rate somewhat comparable with GlyPro-AMCC (Fig. 4C) . A low rate of hydrolysis was obtained with formylGly-Pro-AMCC, but no cleavage of succinyl-, Z-, biotinyl-, or Ac-ThrSer-Gly-Pro-AMCC substrates was observed at concentrations up to 1 mM, indicating that DPP-4 does not tolerate N-acyl-Gly-Pro-based substrates. DPP-4 also showed little activity against commercially available
Ac-Gly-BoroPro Selectively Inhibits FAP-Having defined N-acylGly-Pro dipeptides as FAP-selective substrates, we next asked whether the Ac-Gly-Pro motif would confer FAP-selective inhibition. For this, we coupled the Ac-Gly-Pro specificity motif to an electrophilic boronic acid moiety capable of reacting with the active site serine of the protease (42) . The resulting peptide boronic acid, Ac-Gly-BoroPro, was then tested for FAP and DPP-4 inhibition. FAP reacted readily with submicromolar concentrations of Ac-Gly-BoroPro, reaching steady state inhibition levels rapidly as shown in the progress curves of Fig. 5A . In contrast, DPP-4 required higher Ac-Gly-BoroPro concentrations for inhibition and a longer time to reach steady state inhibition levels (Fig.  5B) . The steady states of product formation in the absence (v 0 ) and presence (v i ) of inhibitor were used to calculate apparent inhibition constants (K iapp ) by plotting v 0 /v i Ϫ 1 against inhibitor concentration (Fig. 5, C and D) . The calculated inhibition constants (K i ) were 23 Ϯ 3 nM for FAP and 377 Ϯ 18 nM for DPP-4 ( Table 2 and Structure 1), indicating an ϳ16-fold selectivity for FAP inhibition.
Besides FAP and DPP-4, the prolyl peptidase family includes DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase, and many of these proteases show ubiquitous distribution (14) . To establish whether Ac-Gly-BoroPro inhibits these prolyl peptidases we cloned and expressed each protease and established assays to monitor their activity. K m values determined in these assays are given in supplemental Table S1 . Next, we determined K i values for their inhibition by Ac-Gly-BoroPro using the progress curve method described above. Strikingly, Ac-Gly-BoroPro inhibited these prolyl peptidases with K i values ranging from ϳ9-to ϳ5400-fold higher than that for FAP inhibition (Table 2 and Structure 1), indicating that the Ac-Gly-Pro motif confers significant FAP selectivity.
DISCUSSION
FAP remains invalidated as a therapeutic target because attempts to fully block FAP activity with antibodies have not been successful (43) and FAP-selective small molecule inhibitors have not been developed. In this study, we identified Ac-Gly-Pro as a FAP-selective substrate motif and developed a FAP-selective inhibitor, Ac-Gly-BoroPro, based on this motif. Our results highlight the unique substrate specificity of FAP and suggest that N-acyl-Gly-Pro-based inhibitors will allow testing the potential of FAP as a therapeutic target.
Our data define FAP as a dual activity protease, having both dipeptidase and Gly-Pro-cleaving endopeptidase activity. This substrate specificity distinguishes FAP from other prolyl peptidases that act as single activity proteases, including DPPs-4, -7, -8, and -9, which act solely as dipeptidases (22, 23, 44 -46) , and prolyl oligopeptidase, which displays only endopeptidase activity (13) . Additionally, the dual activity of FAP is distinct from acylpeptide hydrolase (47) and prolyl carboxypeptidase (48) , which lack both dipeptidase and endopeptidase activity. Acylpeptide hydrolase acts as an N-acetyl amino acid hydrolase, and prolyl carboxypeptidase acts as a Pro-X carboxypeptidase. Thus, the unique substrate specificity of FAP is distinct from other prolyl peptidases.
Determination of the dipeptide specificity of FAP provides insight into potential biological substrates and is in accord with known macromolecular substrates of the protease. Although endogenous FAP dipeptidase substrates are unknown, the broad specificity observed with the P 2 -Pro 1 substrates suggests that FAP, like DPP-4, may cleave bioactive peptides beginning with a P 2 -Pro 1 motif. Cancer-associated cytokines and chemokines represent such potential dipeptidase substrates. For endopeptidase substrates, the Gly 2 -Pro 1 requirement we observed with acetylated dipeptide substrates is similarly found in the FAP cleavage site in ␣ 2 -antiplasmin (TSGP 12 -N 13 Q) (28) and probable cleavage sites in gelatin. We have also confirmed the Gly 2 -Pro 1 requirement using intramolecularly quenched fluorescent substrates and demonstrated that FAP prefers small uncharged amino acids at P 3 , but lacks specificity at P 4 , P 1 Ј, and P 2 .
3 Together, the data suggest that the Gly 2 -Pro 1 motif is a critical determinant of FAP endopeptidase activity.
Based on the unique reactivity of FAP with N-acyl-Gly-Pro-based substrates, we developed Ac-Gly-BoroPro, which selectively inhibited FAP relative to other prolyl peptidases. This selectivity profile and the N-acyl linkage in Ac-Gly-BoroPro differentiate it from other boronic acid inhibitors targeting prolyl peptidases, including Val-BoroPro (30 -32) , N-alkyl-Gly-BoroPro (49) inhibitors, and Boro-norleucine (32) inhibitors. Val-BoroPro and N-alkyl-Gly-BoroPro inhibitors target most prolyl peptidases, whereas Boro-norleucine-based inhibitors selectively target DPP-7. Additionally, these inhibitors contain a free amine at their N terminus, which allows intra-molecular reaction with the electrophilic boron, resulting in cyclization and inhibitor inactivation. In contrast, the N-acyl-linkage in Ac-Gly-BoroPro blocks the N terminus of the inhibitor, making it less nucleophilic and therefore unlikely to cyclize. Importantly, Ac-Gly-BoroPro shows poor reactivity with DPP-8 and DPP-9 as selective inhibition of these proteases causes severe toxicity in animals (50) . Specific areas for in vivo testing of FAP-selective inhibitors will include not only cancer but also other biological processes in which FAP may act, such as cirrhosis (51) and hematopoiesis (52) .
Although FAP and DPP-4 share a high sequence identity, our data show that each has distinct activity, with DPP-4 acting as a dipeptidase and FAP functioning as both a dipeptidase and narrow specificity endopeptidase. Recent structural studies with each protease (15, 21) suggest a mechanistic explanation for our results, as illustrated in Fig. 6 . In Fig. 6A , the crystal structure of DPP-4 covalently bound to diprotinA (Ile-Pro-Ile) illustrates the interactions between this protease and a low STRUCTURE 1 (21) . Carbon atoms of the inhibitor are colored yellow and the boron in pink. Note that the N terminus of the inhibitor is acetylated and therefore not positively charged like the N terminus of the dipeptidase substrate depicted in panel A. The P 2 residue must adopt a positive dihedral angle for the protease to accommodate the N-terminal acetyl group which is circled. The only amino acid that can readily adopt a positive dihedral angle is glycine. C, surface presentation of FAP with the Ac-Gly-BoroPro inhibitor docked into the substrate binding site of the protease to illustrate the steric requirements for the P 2 residue. The carbon atoms of the inhibitor are indicated in yellow, the boron in pink, and the N-terminal acetyl group is circled. The left panel shows the acetyl group of the inhibitor in the accepted position with the P 2 Gly in the positive conformation (ϩ⌽). The right panel depicts the acetyl group of the inhibitor in the non-accepted position with the P 2 Gly in the negative conformation (Ϫ⌽). Note when the glycine adopts a negative dihedral angle steric clashes occur between the N-terminal acetyl group of the inhibitor and the protease.
turnover dipeptidase substrate. Superposition of this crystal structure onto the structure of FAP shows that key substrate binding residues in both proteins are in very similar positions and that diprotinA readily fits into the active site of each protease (Fig. 6A) . Note that the P 2 Ile residue of the substrate contains an aliphatic side chain and a free N terminus that is positively charged. The aliphatic side chain is oriented outward, away from the protease. This orientation can accommodate side chains of various sizes, which explains the broad P 2 dipeptidase specificity we observed with each protease. In contrast, the N terminus of the P 2 Ile is oriented toward the protease and hydrogen bonds with Glu-203, Glu-204, and Tyr-656. Because of this orientation, a P 3 substrate residue cannot be accommodated.
To understand how FAP and DPP-4 interact with an endopeptidase inhibitor, we modeled Ac-Gly-BoroPro into the active site of each protease as shown in Fig. 6B . Compared with the dipeptidase substrate in Fig. 6A , the inhibitor contains an additional peptide bond linking the P 2 Gly residue to the acetyl group. The acetyl group therefore mimics a P 3 residue, and the N terminus is no longer positively charged. The protease can only accommodate the acetyl group when the P 2 residue adopts a conformation with a positive dihedral angle as illustrated in Fig. 6B and the left panel of 6C. When the P 2 residue assumes a negative conformation (Fig. 6C, right panel) , the acetyl group of the inhibitor sterically clashes with the protease. Thus, endopeptidase substrates and inhibitors must contain an amino acid able to adopt a positive dihedral angle to avoid this clash. Glycine is the only natural amino acid that meets this criterion, explaining the requirement of FAP for endopeptidase substrates and inhibitors with a Gly at P 2 .
Based on the superposition of FAP and DPP-4 it is more difficult to comprehend why DPP-4 does not share the endopeptidase activity of FAP. Both proteases readily accommodate the endopeptidase inhibitor Ac-Gly-BoroPro (Fig. 6B) , and they differ only in a single position near the N terminus of P 2 : FAP Ala-657, which corresponds to Asp-663 in DPP-4 (Fig. 6, A and B) . Aertgeerts et al. (15) recently interchanged the Ala and Asp residues using site-directed mutagenesis and showed that the presence of Asp at position 657/663 markedly favors dipeptidase activity, whereas Ala at this position allows endopeptidase activity. These data suggest that increased acidity near the active site provided by the Asp confers a requirement for substrates with a free N terminus. The mechanism by which Ala-657 allows endopeptidase activity remains unclear and warrants future study. In summary, we have defined the dipeptide substrate specificity of FAP and developed the FAP-selective inhibitor, Ac-Gly-BoroPro, based on FAP substrate preferences. Our findings distinguish FAP from other prolyl peptidases and suggest that N-acyl-Gly-Pro-based inhibitors will aid in elucidating FAP biology and utility as a potential therapeutic target.
